Cargando…
P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171701/ http://dx.doi.org/10.1097/01.HS9.0000936352.84768.4d |
| _version_ | 1785039479114825728 |
|---|---|
| author | Gertz, M. Cohen, A. Comenzo, R. Kastritis, E. Landau, H. Libby, E. Liedtke, M. Sanchorawala, V. Schönland, S. Wechalekar, A. Ando, Y. Koh, Y. Zonder, J. Palladini, G. Nie, C. Karp, C. Jin, Y. Conrad, A. Kinney, G. Merlini, G. |
| author_facet | Gertz, M. Cohen, A. Comenzo, R. Kastritis, E. Landau, H. Libby, E. Liedtke, M. Sanchorawala, V. Schönland, S. Wechalekar, A. Ando, Y. Koh, Y. Zonder, J. Palladini, G. Nie, C. Karp, C. Jin, Y. Conrad, A. Kinney, G. Merlini, G. |
| author_sort | Gertz, M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10171701 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101717012023-05-11 P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES Gertz, M. Cohen, A. Comenzo, R. Kastritis, E. Landau, H. Libby, E. Liedtke, M. Sanchorawala, V. Schönland, S. Wechalekar, A. Ando, Y. Koh, Y. Zonder, J. Palladini, G. Nie, C. Karp, C. Jin, Y. Conrad, A. Kinney, G. Merlini, G. Hemasphere Poster Lippincott Williams & Wilkins 2023-05-09 /pmc/articles/PMC10171701/ http://dx.doi.org/10.1097/01.HS9.0000936352.84768.4d Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Poster Gertz, M. Cohen, A. Comenzo, R. Kastritis, E. Landau, H. Libby, E. Liedtke, M. Sanchorawala, V. Schönland, S. Wechalekar, A. Ando, Y. Koh, Y. Zonder, J. Palladini, G. Nie, C. Karp, C. Jin, Y. Conrad, A. Kinney, G. Merlini, G. P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES |
| title | P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES |
| title_full | P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES |
| title_fullStr | P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES |
| title_full_unstemmed | P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES |
| title_short | P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES |
| title_sort | p56 survival benefit of birtamimab in mayo stage iv al amyloidosis in the phase 3 vital study was consistent across all key baseline variables |
| topic | Poster |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171701/ http://dx.doi.org/10.1097/01.HS9.0000936352.84768.4d |
| work_keys_str_mv | AT gertzm p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT cohena p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT comenzor p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT kastritise p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT landauh p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT libbye p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT liedtkem p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT sanchorawalav p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT schonlands p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT wechalekara p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT andoy p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT kohy p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT zonderj p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT palladinig p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT niec p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT karpc p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT jiny p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT conrada p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT kinneyg p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables AT merlinig p56survivalbenefitofbirtamimabinmayostageivalamyloidosisinthephase3vitalstudywasconsistentacrossallkeybaselinevariables |